SBS-226 is a dual mu opiate receptor (MOR) partial agonist and delta opiate receptor (DOR) full antagonist in development for opiate use disorder (OUD) and Opiate Withdrawal Syndrome (OWS) Grant…
Read More
Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board (SAB) with the appointments of Eric Nestler, M.D./PhD, Frances Levin M.D.…
Read More
SBS-1000 was shown to be safe and well tolerated in healthy volunteers in this Phase 1 Single Ascending Dose (SAD) study No serious adverse events observed Sedation at higher doses…
Read More
Sparian Biosciences, Inc. (“Sparian”) submitted testimony to the United States Senate Committee on Finance on the fentanyl public health crisis. Sparian, a clinical-stage biopharmaceutical company, is developing novel therapeutics to…
Read More
Sparian Biosciences, Inc. (“Sparian”) submitted testimony on May 23, 2024, urging the United States Senate to provide the National Institutes of Health (NIH) with the resources to combat the substance…
Read More
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g., cocaine and methamphetamine) Grant awarded by National Institutes of Health…
Read More
SBS-1000 is the first arylepoxamide agonist for the treatment of pain to receive IND clearance Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, and analgesic efficacy of SBS-1000…
Read More
SBS-1000 is the first arylepoxamide agonist for the treatment of pain to receive IND clearance Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and analgesic efficacy of SBS-1000…
Read More
